Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1488 - A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors

Date

10 Oct 2016

Session

Poster display

Presenters

Alexander Drilon

Citation

Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368

Authors

A. Drilon1, D. Hong2, J. Deeken3, S. Smith4, M. Reynolds4, S. Cruickshank4, M. Deegan4, N. Ku4, D. Hyman5

Author affiliations

  • 1 Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Investigational Cancer Therapeutics, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Medical Oncology, Inova Cancer Center, 22031 - Fairfax/US
  • 4 Clinical Research, Loxo Oncology, Inc, 06901 - Stamford/US
  • 5 Investigational Therapeutics, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
More

Resources

Abstract 1488

Background

The TRK family of neurotrophin receptors (TRKA, TRKB, and TRKC encoded by NTRK1, NTRK2, and NTRK3 genes, respectively) and their ligands regulate growth, differentiation and survival of neurons. Fusions of NTRK genes which involve the kinase domain are oncogenic and have been identified across common tumor types. Fusions occur at a frequency of

Trial design

The phase II global study of LOXO-101 (NCT02576431) is an open-label, multi-center trial for patients with any type of advanced solid tumor or primary CNS malignancy harboring an NTRK fusion. Patients age 12 and older with NTRK1, 2, or 3 fusion-positive solid tumors who have progressed following standard therapy are eligible. Prior progression with an investigational or approved agent targeting TRK is an exclusion; intolerance to a prior inhibitor is allowed. The primary endpoint of the study is overall response rate by RECIST 1.1 or RANO. Key secondary endpoints include duration of response, percent tumor regression as best response, PFS and duration of OS. Patients undergo radiographic evaluation for their disease at regular intervals. LOXO-101 is administered orally BID in capsule form starting at 100mg for continuous 28-day cycles. Archival tissue and/ or fresh tissue are required for future molecular assessment

Clinical trial identification

NCT 02576431 release date: 12 October 2015 EudraCT 2015-003582-28 release date: 14 April 2016

Legal entity responsible for the study

Loxo Oncology, Inc

Funding

Loxo Oncology, Inc

Disclosure

D. Hong: Travel support from Loxo Oncology, Inc. S. Smith, M. Reynolds, S. Cruickshank: Paid consultant for Loxo Oncology, Inc. M. Deegan, N. Ku: Employee and stockholder of Loxo Oncology, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings